{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:46:30Z","timestamp":1790343990320,"version":"4.1.0"},"reference-count":72,"publisher":"Radcliffe Medical Media Ltd","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur Cardiol"],"abstract":"<jats:p>In Asia, especially Vietnam, AF is a common arrhythmia and is linked to a higher risk of stroke and systemic embolism. Anticoagulation therapy for stroke prevention in AF patients can result in bleeding complications. To effectively manage AF, adopting appropriate anticoagulation and addressing modifiable risk factors are crucial. Vietnamese clinicians are particularly interested in non-vitamin K antagonist oral anticoagulants (NOACs), a recent development in AF treatment. However, the lack of head-to-head trials comparing NOACs makes selecting a specific NOAC challenging. This review aims to provide a comprehensive overview of the available clinical evidence on NOACs for stroke prevention in AF to assist clinicians in making informed decisions and improving treatment outcomes in patients with AF. The first part of this review will present the current landscape of AF in Vietnam, focusing on AF prevalence and highlighting gaps in clinical practice. Furthermore, this part extensively discusses the anticoagulation strategy for both primary and secondary stroke prevention in AF.<\/jats:p>","DOI":"10.15420\/ecr.2023.24","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T11:26:51Z","timestamp":1702639611000},"source":"Crossref","is-referenced-by-count":7,"title":["Selection of Non-vitamin K Antagonist Oral Anticoagulant for Stroke Prevention in Atrial Fibrillation Based on Patient Profile: Perspectives from Vietnamese Experts. Part 1"],"prefix":"10.15420","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5226-5372","authenticated-orcid":false,"given":"Tri Huynh Quang","family":"Ho","sequence":"first","affiliation":[{"name":"Surgical Intensive Care Unit, Heart Institute, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh That","family":"Ton","sequence":"additional","affiliation":[{"name":"Tam Duc Heart Hospital, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viet Lan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Vietnam Heart Institute, Bach Mai Hospital, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung Manh","family":"Pham","sequence":"additional","affiliation":[{"name":"Vietnam Heart Institute, Bach Mai Hospital, Hanoi, Vietnam; Hanoi Medical University, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-648X","authenticated-orcid":false,"given":"Sy Van","family":"Hoang","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Cho Ray Hospital, Ho Chi Minh City, Vietnam; University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhan Thanh","family":"Vo","sequence":"additional","affiliation":[{"name":"Cardiovascular Department, Cho Ray Hospital, Ho Chi Minh City, Vietnam; Cardiovascular Center, Vinmec Hospital, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thai Quoc","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Vietnam Heart Institute, Bach Mai Hospital, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linh Tran","family":"Pham","sequence":"additional","affiliation":[{"name":"Vietnam Heart Institute, Bach Mai Hospital, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7210-3522","authenticated-orcid":false,"given":"Ton Duy","family":"Mai","sequence":"additional","affiliation":[{"name":"Hanoi Medical University, Hanoi, Vietnam; Stroke Center, Bach Mai Hospital, Hanoi, Vietnam; VNU-University of Medicine and Pharmacy, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6057-8379","authenticated-orcid":false,"given":"Thang Huy","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Cerebrovascular Disease Department, People\u2019s 115 Hospital, Ho Chi Minh City, Vietnam; Pham Ngoc Thach University of Medicine, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6096","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Elliott AD, Middeldorp ME, Van Gelder IC, et al. Epidemiology and modifiable risk factors for atrial fibrillation. Nat Rev Cardiol 2023;20:404\u201317. https:\/\/doi.org\/10.1038\/s41569-022-00820-8; PMID:\u00a036600003.","DOI":"10.1038\/s41569-022-00820-8"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Zulkifly H, Lip GYH, Lane DA. Epidemiology of atrial fibrillation. Int J Clin Pract 2018;72:e13070. https:\/\/doi.org\/10.1111\/ijcp.13070; PMID:\u00a029493854.","DOI":"10.1111\/ijcp.13070"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Chao TF, Liu CJ, Tuan TC, et al. Lifetime risks, projected numbers, and adverse outcomes in Asian patients with atrial fibrillation: a report from the Taiwan nationwide AF cohort study. Chest 2018;153:453\u201366. https:\/\/doi.org\/10.1016\/j.chest.2017.10.001; PMID:\u00a029017957.","DOI":"10.1016\/j.chest.2017.10.001"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N\u20139N. https:\/\/doi.org\/10.1016\/s0002-9149(98)00583-9; PMID:\u00a09809895.","DOI":"10.1016\/s0002-9149(98)00583-9"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham study. Stroke 1996;27:1760\u20134. https:\/\/doi.org\/10.1161\/01.str.27.10.1760; PMID:\u00a08841325.","DOI":"10.1161\/01.str.27.10.1760"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Michaud GF, Stevenson WG. Atrial fibrillation. N Engl J Med 2021;384:353\u201361. https:\/\/doi.org\/10.1056\/NEJMcp2023658; PMID:\u00a033503344.","DOI":"10.1056\/NEJMcp2023658"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857\u201367. https:\/\/doi.org\/10.7326\/0003-4819-146-12-200706190-00007; PMID:\u00a017577005.","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Piccini JP, Hernandez AF, Zhao X, et al. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J Am Coll Cardiol 2009;54:1280\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2009.04.091; PMID:\u00a019778670.","DOI":"10.1016\/j.jacc.2009.04.091"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Albers GW, Yim JM, Belew KM, et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996;156:2311\u20136. https:\/\/doi.org\/10.1001\/archinte.1996.00440190053006; PMID:\u00a08911237.","DOI":"10.1001\/archinte.1996.00440190053006"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955\u201362. https:\/\/doi.org\/10.1016\/S0140-6736(13)62343-0; PMID:\u00a024315724.","DOI":"10.1016\/s0140-6736(13)62343-0"},{"key":"ref10","unstructured":"Haas S, Camm JA, Harald D, et al. GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide. Clin Res Cardiol 2023;112:759\u201371. https:\/\/doi.org\/10.1007\/s00392-022-02079-y; PMID:\u00a036094573."},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Chao TF, Chiang CE, Lin YJ, et al. Evolving changes of the use of oral anticoagulants and outcomes in patients with newly diagnosed atrial fibrillation in Taiwan. Circulation 2018;138:1485\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.036046; PMID:\u00a030354355.","DOI":"10.1161\/circulationaha.118.036046"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"January CT, Wann LS, Calkins H, et al. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. Circulation 2019;140:e125\u201351. https:\/\/doi.org\/10.1161\/CIR.0000000000000665; PMID:\u00a030686041.","DOI":"10.1161\/CIR.0000000000000719"},{"key":"ref13","unstructured":"Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42:373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612; PMID:\u00a032860505."},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Wu X, Cao S, Yu B, He T. Comparing the efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients with antiphospholipid syndrome: a systematic review and meta-analysis. Blood Coagul Fibrinolysis 2022;33:389\u2013401. https:\/\/doi.org\/10.1097\/MBC.0000000000001153; PMID:\u00a035867933.","DOI":"10.1097\/mbc.0000000000001153"},{"key":"ref15","unstructured":"Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med 2022;387:978\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2209051; PMID:\u00a036036525."},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Eikelboom JW, Connolly SJ, Brueckmann M, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013;369:1206\u201314. https:\/\/doi.org\/10.1056\/NEJMoa1300615; PMID:\u00a023991661.","DOI":"10.1056\/nejmoa1300615"},{"key":"ref17","unstructured":"World Health Organization. Cardiovascular diseases (CVD) in Vietnam. https:\/\/www.who.int\/vietnam\/health-topics\/cardiovascular-diseases (accessed 17 May 2023)."},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Son PT, Quang NN, Viet NL, et al. Prevalence, awareness, treatment and control of hypertension in Vietnam \u2013 results from a national survey. J Hum Hypertens 2012;26:268\u201380. https:\/\/doi.org\/10.1038\/jhh.2011.18; PMID:\u00a021368775.","DOI":"10.1038\/jhh.2011.18"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Bao TQ, Hoang VM, Lan VH, et al. Risk factors for non-communicable diseases among adults in Vietnam: findings from the Vietnam STEPS survey 2015. J Glob Health Sci 2020;2:e7. https:\/\/doi.org\/10.35500\/jghs.2020.2.e7.","DOI":"10.35500\/jghs.2020.2.e7"},{"key":"ref20","unstructured":"Lien NTB. Prevalence and risk factors of atrial fibrillation. J Pract Med 2013;5:72\u20135 [in Vietnamese]."},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Nguyen TN, Huyen VT, Nguyen TX, et al. Prevalence, risk factors and pharmacological treatment of atrial fibrillation in older hospitalized patients in Vietnam. Int Cardiovasc Forum 2016;8:79\u201384. https:\/\/doi.org\/10.17987\/icfj.v8i0.339.","DOI":"10.17987\/icfj.v8i0.339"},{"key":"ref22","unstructured":"Do MC, Cao PP. Predictors of poor outcomes after ischemic stroke in patients with atrial fibrillation. Ho Chi Minh City Med J 2015;19:240\u20135. [in Vietnamese]"},{"key":"ref23","unstructured":"Lien N. Clinical and subclinical characteristics and risk factors of stroke in patients with acute cerebral infarction with nonvalvular atrial fibrillation (2019). https:\/\/sdh.hmu.edu.vn\/news\/cID439_dac-diem-lam-sang-can-lam-sang-cac-yeu-to-nguy-co-dot-quy-cua-nhoi-mau-nao-cap-o-benh-nhan-rung-nhi-khong-do-benh-van-tim.html (accessed 19 December 2022)."},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Binh V, Toan M. Clinical characteristics, risk factors of patients with non-valvular atrial fibrillation treated at Th\u00e1i Binh Medical University Hospital. VMJ 2022 514;2: 318\u201322 [in Vietnamese]. https:\/\/doi.org\/10.51298\/vmj.v514i2.2657.","DOI":"10.51298\/vmj.v514i2.2657"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Kh\u00f4i VH, Nga LT. Clinical features and outcome ischemic stroke patients with atrial fibrillation. VMJ 2022 510;1:235\u20138 [in Vietnamese]. https:\/\/doi.org\/10.51298\/vmj.v514i2.2657.","DOI":"10.51298\/vmj.v514i2.2657"},{"key":"ref26","unstructured":"Mai TTP, Dung HT, Hien PTT, et al. Evaluation of pharmacists\u2019 role in rational use of antithrombotic drugs in patients with non-valvular atrial fibrillation. J Pharm Sci 2016;43:85\u201390. https:\/\/doi.org\/10.14456\/mujps.2016.10."},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Chiang CE, Wang KL, Lin SJ. Asian strategy for stroke prevention in atrial fibrillation. Europace 2015;17(Suppl 2):ii31\u20139. https:\/\/doi.org\/10.1093\/europace\/euv231; PMID:\u00a026842113.","DOI":"10.1093\/europace\/euv231"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Siu CW, Lip GYH, Lam KF, Tse HF. Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong. Heart Rhythm 2014;11:1401\u20138. https:\/\/doi.org\/10.1016\/j.hrthm.2014.04.021; PMID:\u00a024747420.","DOI":"10.1016\/j.hrthm.2014.04.021"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Friberg L, Rosenqvist M, Lip GYH. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182\u00a0678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study. Eur Heart J 2012;33:1500\u201310. https:\/\/doi.org\/10.1093\/eurheartj\/ehr488; PMID:\u00a022246443.","DOI":"10.1093\/eurheartj\/ehr488"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Staerk L, Sherer JA, Ko D, et al. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res 2017;120:1501\u201317. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.309732; PMID:\u00a028450367.","DOI":"10.1161\/circresaha.117.309732"},{"key":"ref31","unstructured":"Huong P, Giang T, Dung V, Giang L. Adherence to vitamin K antagonist treatment among patients with atrial fibrillation at Quang Ninh General Hospital. J Nurs Sci 2020;3:106\u2013115."},{"key":"ref32","unstructured":"Nguyen NQ, Dang VD. Levels of knowledge about using oral anticoagulants of patient with non-valvular atrial fibrillation at military Central Hospital 108. J Nurs Sci 2022;5:34\u201343."},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Zawawi NA, Abdul Halim Zaki I, Ming LC, et al. Anticoagulation control in different ethnic groups receiving vitamin K antagonist for stroke prevention in atrial fibrillation. Front Cardiovasc Med 2021;8:736143. https:\/\/doi.org\/10.3389\/fcvm.2021.736143; PMID:\u00a034869639.","DOI":"10.3389\/fcvm.2021.736143"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Mak M, Lam C, Pineda SJ, et al. Pharmacogenetics of warfarin in a diverse patient population. J Cardiovasc Pharmacol Ther 2019;24:521\u201333. https:\/\/doi.org\/10.1177\/1074248419843530; PMID:\u00a031064211.","DOI":"10.1177\/1074248419843530"},{"key":"ref35","unstructured":"Minh TT, Phuoc DV, Viet NL, et al. Vietnam Heart Association: guideline diagnosis and treatment of atrial fibrillation. Vietnam National Heart Association; 2022. [In Vietnamese]"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Wang KL, Lip GYH, Lin SJ, Chiang CE. Non-vitamin K antagonist oral anticoagulants for stroke prevention in Asian patients with nonvalvular atrial fibrillation: meta-analysis. Stroke 2015;46:2555\u201361. https:\/\/doi.org\/10.1161\/STROKEAHA.115.009947; PMID:\u00a026304863.","DOI":"10.1161\/strokeaha.115.009947"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Yang K-T, Sun W-C, Tsai T-J, et al. The risk of gastrointestinal bleeding between non-vitamin K antagonist oral anticoagulants and vitamin K antagonists in the Asian atrial fibrillation patients: a meta-analysis. Int J Environ Res Public Health 2021;18:137. https:\/\/doi.org\/10.3390\/ijerph18010137; PMID:\u00a033375495.","DOI":"10.3390\/ijerph18010137"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Lee E, Choi EK, Han KD, et al. Mortality and causes of death in patients with atrial fibrillation: a nationwide population-based study. PLoS One 2018;13:e0209687. https:\/\/doi.org\/10.1371\/journal.pone.0209687; PMID:\u00a030586468.","DOI":"10.1371\/journal.pone.0209687"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012;11:315\u201322. https:\/\/doi.org\/10.1016\/S1474-4422(12)70042-X; PMID:\u00a022402056.","DOI":"10.1016\/s1474-4422(12)70042-x"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Rost NS, Giugliano RP, Ruff CT, et al. Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: findings from ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). Stroke 2016;47:2075\u201382. https:\/\/doi.org\/10.1161\/STROKEAHA.116.013540; PMID:\u00a027387994.","DOI":"10.1161\/strokeaha.116.013540"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Easton JD, Lopes RD, Bahit MC, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the Aristotle trial. Lancet Neurol 2012;11:503\u201311. https:\/\/doi.org\/10.1016\/S1474-4422(12)70092-3; PMID:\u00a022572202.","DOI":"10.1016\/s1474-4422(12)70092-3"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Diener HC, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010;9:1157\u201363. https:\/\/doi.org\/10.1016\/S1474-4422(10)70274-X; PMID:\u00a021059484.","DOI":"10.1016\/s1474-4422(10)70274-x"},{"key":"ref43","unstructured":"Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011;365:981\u201392. https:\/\/doi.org\/10.1056\/NEJMoa1107039; PMID:\u00a021870978."},{"key":"ref44","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139\u201351. https:\/\/doi.org\/10.1056\/NEJMoa0905561; PMID:\u00a019717844."},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Skaistis J, Tagami T. Risk of fatal bleeding in episodes of major bleeding with new oral anticoagulants and vitamin K antagonists: a systematic review and meta-analysis. PLoS One 2015;10:e0137444. https:\/\/doi.org\/10.1371\/journal.pone.0137444; PMID:\u00a026383245.","DOI":"10.1371\/journal.pone.0137444"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Alberts M, Chen YW, Lin JH, et al. Risks of stroke and mortality in atrial fibrillation patients treated with rivaroxaban and warfarin. Stroke 2020;51:549\u201355. https:\/\/doi.org\/10.1161\/STROKEAHA.119.025554; PMID:\u00a031888412.","DOI":"10.1161\/strokeaha.119.025554"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Larsen TB, Skj\u00f8th F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 2016;353:i3189. https:\/\/doi.org\/10.1136\/bmj.i3189; PMID:\u00a027312796.","DOI":"10.1136\/bmj.i3189"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Yasaka M, Uchiyama S, Atarashi H, et al. Dabigatran for Japanese patients with atrial fibrillation and prior stroke: a subgroup analysis of the J-Dabigatran surveillance program. J Stroke Cerebrovasc Dis 2020;29:104717. https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2020.104717; PMID:\u00a032113736.","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104717"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Minh TT, Tri HHQ, Lan N, et al. Selection of non-vitamin k antagonist oral anticoagulant for stroke prevention in atrial fibrillation based on patient profile: perspectives from Vietnamese experts. Part 2. Eur Cardiol 2023;18:e62. https:\/\/doi.org\/10.15420\/ecr.2023.25.","DOI":"10.15420\/ecr.2023.25"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Ho\u00e0ng LG, B\u00ecnh HA. To evaluate of risk factors by CHA2DS2-VASc score in patients are diagnosed stroke with non-valvular atrial fibrillation. Viet J Diabetes Endocrinol 2021;44:71\u201381 [in Vietnamese]. https:\/\/doi.org\/10.47122\/vjde.2020.44.10.","DOI":"10.47122\/vjde.2020.44.10"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Nguyen TH, Gall S, Cadilhac DA, et al. Processes of stroke unit care and outcomes at discharge in Vietnam: findings from the registry of stroke care quality (RES-Q) in a major public hospital. J Stroke Med 2019;2:119\u201327. https:\/\/doi.org\/10.1177\/2516608519869132.","DOI":"10.1177\/2516608519869132"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Ton MD, Dao PV, Nguyen DT, et al. Sex disparity in stroke outcomes in a multicenter prospective stroke registry in Vietnam. Int J Stroke 2023. https:\/\/doi.org\/10.1177\/17474930231177893; PMID:\u00a037190749; epub ahead of press.","DOI":"10.1177\/17474930231177893"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Pham TL, Blizzard L, Srikanth V, et al. Case-fatality and functional status three months after first-ever stroke in Vietnam. J Neurol Sci 2016;365:65\u201371. https:\/\/doi.org\/10.1016\/j.jns.2016.03.013; PMID:\u00a027206877.","DOI":"10.1016\/j.jns.2016.03.013"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369:2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1310907; PMID:\u00a024251359.","DOI":"10.1056\/NEJMoa1310907"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365:883\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1009638; PMID:\u00a021830957.","DOI":"10.1056\/nejmoa1009638"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"Ntaios G, Papavasileiou V, Diener HC, et al. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke 2017;12:589\u201396. https:\/\/doi.org\/10.1177\/1747493017700663; PMID:\u00a028730948.","DOI":"10.1177\/1747493017700663"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Diener HC, Hankey GJ, Easton JD, et al. Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation. Eur Heart J Suppl 2020;22(Suppl I):I13\u201321. https:\/\/doi.org\/10.1093\/eurheartj\/suaa104; PMID:\u00a033093818.","DOI":"10.1093\/eurheartj\/suaa104"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Rasmussen LH, Larsen TB, Graungaard T, et al. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. BMJ 2012;345:e7097. https:\/\/doi.org\/10.1136\/bmj.e7097; PMID:\u00a023129490.","DOI":"10.1136\/bmj.e7097"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Thu Hien NT, Thong TH, Tung LT, et al. Dysphagia and associated factors among patients with acute ischemic stroke in Vietnam. Ann Med Surg (Lond) 2022;84:104887. https:\/\/doi.org\/10.1016\/j.amsu.2022.104887; PMID:\u00a036536715.","DOI":"10.1016\/j.amsu.2022.104887"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Coleman CI, Peacock WF, Bunz TJ, Alberts MJ. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and previous stroke or transient ischemic attack. Stroke 2017;48:2142\u20139. https:\/\/doi.org\/10.1161\/STROKEAHA.117.017474; PMID:\u00a028655814.","DOI":"10.1161\/strokeaha.117.017474"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Xian Y, Xu H, O\u2019Brien EC, et al. Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study. JAMA Neurol 2019;76:1192\u2013202. https:\/\/doi.org\/10.1001\/jamaneurol.2019.2099; PMID:\u00a031329212.","DOI":"10.1001\/jamaneurol.2019.2099"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Guo Z, Ding X, Ye Z, et al. Non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients with previous stroke or intracranial hemorrhage: a systematic review and meta-analysis of observational studies. Clin Cardiol 2021;44:917\u201324. https:\/\/doi.org\/10.1002\/clc.23647; PMID:\u00a034013988.","DOI":"10.1002\/clc.23647"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Hart RG, Coull BM, Hart D. Early recurrent embolism associated with nonvalvular atrial fibrillation: a retrospective study. Stroke 1983;14:688\u201393. https:\/\/doi.org\/10.1161\/01.str.14.5.688; PMID:\u00a06658950.","DOI":"10.1161\/01.str.14.5.688"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 2021;23:1612\u201376. https:\/\/doi.org\/10.1093\/europace\/euab065; PMID:\u00a033895845.","DOI":"10.1093\/europace\/euab157"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Oldgren J, \u00c5sberg S, Hijazi Z, et al. Early versus delayed non-vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation (TIMING): a registry-based randomized controlled noninferiority study. Circulation 2022;146:1056\u201366. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.060666; PMID:\u00a036065821.","DOI":"10.1161\/circulationaha.122.060666"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Waziry R, Claus JJ, Hofman A. Dementia risk following ischemic stroke: a systematic review and meta-analysis of factors collected at time of stroke diagnosis. J Alzheimers Dis 2022;90:1535\u201346. https:\/\/doi.org\/10.3233\/JAD-220317; PMID:\u00a036278345.","DOI":"10.3233\/JAD-220317"},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Lee ZX, Ang E, Lim XT, Arain SJ. Association of risk of dementia with direct oral anticoagulants versus warfarin use in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. J Cardiovasc Pharmacol 2021;77:22\u201331. https:\/\/doi.org\/10.1097\/FJC.0000000000000925; PMID:\u00a033136766.","DOI":"10.1097\/fjc.0000000000000925"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Khurshid R, Awais M, Malik J. Electrophysiology practice in low- and middle-income countries: an updated review on access to care and health delivery. Heart Rhythm O2 2023;4:69\u201377. https:\/\/doi.org\/10.1016\/j.hroo.2022.09.002; PMID:\u00a036713042.","DOI":"10.1016\/j.hroo.2022.09.002"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Santos IS, Goulart AC, Olmos RD, et al. Atrial fibrillation in low- and middle-income countries: a narrative review. Eur Heart J Suppl 2020;22(Suppl O):O61\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/suaa181; PMID:\u00a033380945.","DOI":"10.1093\/eurheartj\/suaa181"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Di Cesare M, Jarvis JD, Scarlatescu O, et al. NOACs added to WHO\u2019s essential medicines list: recommendations for future policy actions. Glob Heart 2020;15:67. https:\/\/doi.org\/10.5334\/gh.774; PMID:\u00a033150132.","DOI":"10.5334\/gh.774"},{"key":"ref71","unstructured":"US Food and Drug Administration. Ascend Laboratories LLC issues voluntary nationwide recall of dabigatran etexilate capsules, USP 75 mg and 150 mg, due to the detection of N-nitroso-dabigatran (NDAB) impurity. 2023. https:\/\/www.fda.gov\/safety\/recalls-market-withdrawals-safety-alerts\/ascend-laboratories-llc-issues-voluntary-nationwide-recall-dabigatran-etexilate-capsules-usp-75-mg (accessed 18 May 2023)."}],"container-title":["European Cardiology Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2023.24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T11:27:14Z","timestamp":1702639634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ecrjournal.com\/articleindex\/ecr.2023.24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":72,"URL":"https:\/\/doi.org\/10.15420\/ecr.2023.24","relation":{},"ISSN":["1758-3764","1758-3756"],"issn-type":[{"value":"1758-3764","type":"electronic"},{"value":"1758-3756","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"article-number":"e61"}}